• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002252.SZ
Share

Shanghai RAAS Blood Products Co., Ltd. Stocks

CN¥ 5.26Last Updated 26.05.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 5.10B

CN¥ 5.26
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, human fibrinogen, human thrombin and human fibrin sealant, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. It also provides testing services for blood products, vaccines, diagnostic reagents, and testing equipment. The company also exports its products to Southeast Asia and Latin America. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 002252.SZ is 6.0 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 16:55

Micro-cap company Astrotech rose 460% in just one day. It's targeting the moon

28.05.2026 16:34

UBS: The world's richest families are reducing their investments in the dollar. Where are they going?

28.05.2026 15:58

Morning in New York: geopolitics and macro statistics sway volatility

28.05.2026 15:12

Traders are upping the ante against small-cap companies. What do they fear?

28.05.2026 14:10

Nebius shares soared: its shareholder turned out to be an important AI investor who worked at OpenAI

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026